Phase IIB Randomized, Placebo-Controlled Trial of ACTOplus Met® XR in Subjects With Stage I-IV Squamous Cell Carcinoma of the Oral Cavity or Oropharynx Prior to Definitive Treatment

Trial Profile

Phase IIB Randomized, Placebo-Controlled Trial of ACTOplus Met® XR in Subjects With Stage I-IV Squamous Cell Carcinoma of the Oral Cavity or Oropharynx Prior to Definitive Treatment

Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Aug 2017

At a glance

  • Drugs Metformin/pioglitazone (Primary)
  • Indications Orofacial cancer; Oropharyngeal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Aug 2017 Status changed from not yet recruiting to recruiting.
    • 13 Jul 2017 Planned End Date changed from 31 Mar 2019 to 10 Jun 2019.
    • 13 Jul 2017 Planned primary completion date changed from 31 Mar 2019 to 10 Jun 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top